| Drug General Information |
| Drug ID |
D05RUJ
|
| Former ID |
DIB007255
|
| Drug Name |
G-1128
|
| Synonyms |
MATAGEN oligonucleotides; Antisense [cancer], Genta/Chugai; Anti-bcr-abl, Genta/Chugai
|
| Drug Type |
Antisense drug
|
| Indication |
Chronic myelogenous leukaemia [ICD9: 205.1; ICD10:C92.1]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
Genta Inc
|
| Target and Pathway |
| Target(s) |
mRNA of Abl |
Target Info |
|
[2]
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Cell cycle
|
|
Axon guidance
|
|
Neurotrophin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemia
|
|
Viral myocarditis
|
|
PANTHER Pathway
|
Axon guidance mediated by Slit/Robo
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
ATM pathway
|
|
Regulation of Telomerase
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
PDGFR-beta signaling pathway
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
p53 pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Regulation of actin dynamics for phagocytic cup formation
|
|
CDO in myogenesis
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
HDR through Single Strand Annealing (SSA)
|
|
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
DNA Damage Response
|
|
ErbB Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by Robo receptor
|
|
Myogenesis
|
|
Factors involved in megakaryocyte development and platelet production
|
|
TP53 Network
|
|
miRNAs involved in DNA damage response
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004653) |
|---|
| REF 2 | Pharmaceutical Design And Development: A Molecular Biology Approach, T V Ramabhadran, 2005. Page(219). |
|---|
